UK Biobank (core renewal)
Lead Research Organisation:
UK Biobank
Department Name: UNLISTED
Abstract
UK Biobank is supported by The Wellcome Trust, The National Institute of Health Research, The Medical Research Council, The British Heart Foundation and Cancer Research UK. The figures presented on this record represent the Medical Research Council funding contribution only with some additional UKRI Infrastructure funds in addition.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
UK Biobank is a prospective study of 500,000 men and women aged 40-69 years at the point of recruitment (2006-10). The study has collected extensive phenotypic and genotypic detail about its participants, including data from questionnaires, physical measures, sample assays, accelerometery, imaging, genome-wide genotyping and long-term longitudinal follow-up for a wide range of health-related outcomes. The resource is regularly augmented with additional data and is available to academic or commercial researchers world-wide to use for any type of health-related research that is in the public interest. It has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. The ongoing identification and adjudication of increasing numbers of incident cases of the commoner conditions in the resource will support extensive and powerful research into their determinants and the range of diseases that can be studied reliably will widen as the numbers of incident events of different types increase during follow-up over the next 5-10 year period. As a result, UK Biobank provides researchers from around the world with greater opportunities to better understand early disease stages and their diagnosis, and can support the development of new treatments for diseases of mid-to-later life.
Technical Summary
The UK Biobank resource has been established primarily for the conduct of prospective studies investigating the relevance of a wide range of exposures to health outcomes that occur during long-term follow-up. There are now sufficient numbers of incident cases of the commoner conditions to support extensive and powerful research into their determinants.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
There is regular augmentation of UK Biobank’s capability for effective use as a prospective resource by the widest possible range of researchers. This activity has included: streamlining resource access management systems; imaging assessments; an agile response to the SARS-2 Covid pandemic; ‘omics; whole genome sequencing and turning biological samples into genotypic and biomarker data to make the resource more accessible to researchers studying a wide range of different conditions.
During the next few years, it is intended to develop UK Biobank as a UK national infrastructure and the resource will move to new premises at the University of Manchester where sample throughput will be accelerated with new robotics and freezer systems, making more large scale studies possible. UK Biobank will make increasing amounts of genotype and biomarker data available. It will seek to extend cohort-wide record linkage to primary care health; develop other linkages relevant to health; complete imaging assessments on close to 100,000 participants, including repeat imaging on a subset; develop and implement further enhancements (such as metabolomics) and introduce changes relating to participant involvement and to address equality diversity and inclusion. Communications will be expanded to a wider audience to help ensure that researchers from around the world are well informed about UK Biobank’s enhanced capabilities in order to maximise suitable use of the resource over the next few years.
Organisations
People |
ORCID iD |
Rory Collins (Principal Investigator) |
Publications
Creed JH
(2019)
Methylmercury exposure, genetic variation in metabolic enzymes, and the risk of glioma.
in Scientific reports
Hoppe L
(2019)
The Associations of Diuretics and Laxatives Use with Cardiovascular Mortality. An Individual Patient-Data Meta-analysis of Two Large Cohort Studies
in Cardiovascular Drugs and Therapy
Allara E
(2019)
Genetic Determinants of Lipids and Cardiovascular Disease Outcomes: A Wide-Angled Mendelian Randomization Investigation.
in Circulation. Genomic and precision medicine
McDonald L
(2019)
Comparison of accelerometer-derived physical activity levels between individuals with and without cancer: a UK Biobank study.
in Future oncology (London, England)
Lourida I
(2019)
Association of Lifestyle and Genetic Risk With Incidence of Dementia.
in JAMA
Stasinopoulos L
(2019)
Association of supplemental calcium and dairy milk intake with all-cause and cause-specific mortality in the UK Biobank: a prospective cohort study
in British Journal of Nutrition
Ni G
(2019)
The genetic relationship between female reproductive traits and six psychiatric disorders.
in Scientific reports
Satizabal CL
(2019)
Genetic architecture of subcortical brain structures in 38,851 individuals.
in Nature genetics
Escott-Price V
(2019)
Polygenic risk for schizophrenia and season of birth within the UK Biobank cohort.
in Psychological medicine
Schoech AP
(2019)
Quantification of frequency-dependent genetic architectures in 25 UK Biobank traits reveals action of negative selection.
in Nature communications
Mulugeta A
(2019)
Depression increases the genetic susceptibility to high body mass index: Evidence from UK Biobank.
in Depression and anxiety
Tamosauskaite J
(2019)
Hereditary Hemochromatosis Associations with Frailty, Sarcopenia and Chronic Pain: Evidence from 200,975 Older UK Biobank Participants.
in The journals of gerontology. Series A, Biological sciences and medical sciences
Quick C
(2019)
emeraLD: rapid linkage disequilibrium estimation with massive datasets.
in Bioinformatics (Oxford, England)
Farmer RE
(2019)
Associations Between Measures of Sarcopenic Obesity and Risk of Cardiovascular Disease and Mortality: A Cohort Study and Mendelian Randomization Analysis Using the UK Biobank.
in Journal of the American Heart Association
Pividori M
(2019)
ukbREST: efficient and streamlined data access for reproducible research in large biobanks.
in Bioinformatics (Oxford, England)
Au Yeung SL
(2019)
Impact of glycemic traits, type 2 diabetes and metformin use on breast and prostate cancer risk: a Mendelian randomization study.
in BMJ open diabetes research & care
Raisi-Estabragh Z
(2020)
Greater risk of severe COVID-19 in Black, Asian and Minority Ethnic populations is not explained by cardiometabolic, socioeconomic or behavioural factors, or by 25(OH)-vitamin D status: study of 1326 cases from the UK Biobank.
in Journal of public health (Oxford, England)
Carvalho-E-Silva AP
(2020)
Does type 2 diabetes increase the risk of musculoskeletal pain? Cross-sectional and longitudinal analyses of UK biobank data.
in Seminars in arthritis and rheumatism
Cherny S
(2020)
Self-reported hearing loss questions provide a good measure for genetic studies: a polygenic risk score analysis from UK Biobank
in European Journal of Human Genetics
Ghorbani Mojarrad N
(2020)
Association Between Polygenic Risk Score and Risk of Myopia.
in JAMA ophthalmology
Trinder M
(2020)
Causal Inference for Genetically Determined Levels of High-Density Lipoprotein Cholesterol and Risk of Infectious Disease
in Arteriosclerosis, Thrombosis, and Vascular Biology
Zhao H
(2020)
Transcriptomic and metabolomic landscape of the molecular effects of glyphosate commercial formulation on Apis mellifera ligustica and Apis cerana cerana.
in The Science of the total environment
Oster J
(2020)
Identification of patients with atrial fibrillation: a big data exploratory analysis of the UK Biobank.
in Physiological measurement
Shafquat A
(2020)
Identifying novel associations in GWAS by hierarchical Bayesian latent variable detection of differentially misclassified phenotypes
in BMC Bioinformatics
McGrath BP
(2020)
Isolated Diastolic Hypertension in the UK Biobank: Comparison of ACC/AHA and ESC/NICE Guideline Definitions.
in Hypertension (Dallas, Tex. : 1979)
Bai WY
(2020)
Identification of PIEZO1 polymorphisms for human bone mineral density.
in Bone
Gellert-Kristensen H
(2020)
Combined Effect of PNPLA3, TM6SF2, and HSD17B13 Variants on Risk of Cirrhosis and Hepatocellular Carcinoma in the General Population.
in Hepatology (Baltimore, Md.)
Cole JH
(2020)
Multimodality neuroimaging brain-age in UK biobank: relationship to biomedical, lifestyle, and cognitive factors.
in Neurobiology of aging
Chen VL
(2020)
Genetic variants that associate with cirrhosis have pleiotropic effects on human traits.
in Liver international : official journal of the International Association for the Study of the Liver
Sukcharoen K
(2020)
IgA Nephropathy Genetic Risk Score to Estimate the Prevalence of IgA Nephropathy in UK Biobank.
in Kidney international reports
Ning Z
(2020)
High-definition likelihood inference of genetic correlations across human complex traits.
in Nature genetics
Falcone GJ
(2020)
Genetically Elevated LDL Associates with Lower Risk of Intracerebral Hemorrhage.
in Annals of neurology
Hodgson K
(2020)
Cannabis use, depression and self-harm: phenotypic and genetic relationships.
in Addiction (Abingdon, England)
Mitani A
(2020)
Detection of anaemia from retinal fundus images via deep learning.
in Nature biomedical engineering
Magnus MC
(2020)
Identifying potential causal effects of age at menarche: a Mendelian randomization phenome-wide association study.
in BMC medicine
Rodrigue AL
(2020)
Genetic Contributions to Multivariate Data-Driven Brain Networks Constructed via Source-Based Morphometry.
in Cerebral cortex (New York, N.Y. : 1991)
Choi J
(2020)
Evaluating polygenic risk scores in assessing risk of nine solid and hematologic cancers in European descendants.
in International journal of cancer
Tuke M
(2020)
Large Copy-Number Variants in UK Biobank Caused by Clonal Hematopoiesis May Confound Penetrance Estimates.
in American journal of human genetics
Persyn E
(2020)
Genome-wide association study of MRI markers of cerebral small vessel disease in 42,310 participants.
in Nature communications
Portas L
(2020)
Lung Development Genes and Adult Lung Function
in American Journal of Respiratory and Critical Care Medicine
Kolin DA
(2020)
Clinical, regional, and genetic characteristics of Covid-19 patients from UK Biobank.
in PloS one
Description | Impact of clinically silent atrial fibrillation on cerebrovascular disease and cognitive decline in the UK Biobank Imaging Cohort |
Amount | £2,474,260 (GBP) |
Funding ID | RG/18/6/33576 |
Organisation | British Heart Foundation (BHF) |
Sector | Charity/Non Profit |
Country | United Kingdom |
Start | 07/2019 |
End | 06/2024 |
Description | UK Biobank - The Repeat Imaging Project |
Amount | £2,500,000 (GBP) |
Funding ID | R39738/CN039 |
Organisation | MRC Dementias Platform UK |
Sector | Academic/University |
Country | United Kingdom |
Start | 04/2019 |
End | 01/2023 |
Description | UK Biobank - Whole genome sequencing of 50,000 UKB participants |
Amount | £30,000,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 03/2020 |
Description | UK Biobank- Expansion of the UKB imaging to a 4th centre and repeat imaging assessment of 10,000 participants |
Amount | £8,500,000 (GBP) |
Organisation | Medical Research Council (MRC) |
Sector | Public |
Country | United Kingdom |
Start | 03/2018 |
End | 12/2022 |
Description | UK Biobank Scientific Conference |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Public/other audiences |
Results and Impact | The UK Biobank Scientific Symposium included presentations about the successes and future plans of the UK Biobank. It took place on 21 June 2018 in London |
Year(s) Of Engagement Activity | 2018 |
Description | UK Biobank participant imaging event |
Form Of Engagement Activity | A formal working group, expert panel or dialogue |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UK Biobank for participants of the imaging work |
Year(s) Of Engagement Activity | 2021 |
Description | UKBiobank participant events - 2014 - 2019 |
Form Of Engagement Activity | Participation in an activity, workshop or similar |
Part Of Official Scheme? | No |
Geographic Reach | National |
Primary Audience | Study participants or study members |
Results and Impact | UKB Biobank participants regularly attend events aimed at informing them about the work being undertaken with their data. Usually, the events last a few hours and include an overview from the chief scientist and two talks from scientists that have used UKB data. From 2014 - 2020 over 4,000 participants have taken part in events in Edinburgh (4), Manchester (4), Nottingham, Leeds, Cardiff (2), Newcastle (5), Glasgow (2), Bristol (2) and Reading(4). They are often over-subscribed and participants leave these events wishing to seek more information and support he programme in new ways (EG in imaging, genome sequencing) |
Year(s) Of Engagement Activity | 2014,2015,2016,2017,2018,2019 |
URL | http://www.ukbiobank.ac.uk |